Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMY13UR)

Drug Name
Kushenol N Drug Info
Synonyms
NSC668937; Kushenol N; 2-(2,4-Dihydroxyphenyl)-3,7-dihydroxy-8-(2-isopropenyl-5-methyl-4-hexenyl)-5-methoxy-2,3-dihydro-4H-chromen-4-one; 102490-65-3; 4H-1-Benzopyran-4-one,2-(2,4-dihydroxyphenyl)-2,3-dihydro-3,7-dihydroxy-5-methoxy-8-[(2R)-5-methyl-2-(1-methylethenyl)-4-hexen-1-yl]-,(2R,3S)-; ACMC-20bulp; AC1Q6KJK; AC1L8I5S; CTK4A1130; DTXSID50327597; NSC-668937; NCI60_024046; 2-(2,4-dihydroxyphenyl)-3,7-dihydroxy-8-(2-isopropenyl-5-methyl-hex-4-enyl)-5-methoxy-chroman-4-one
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
381851
CAS Number
CAS 102490-65-3
TTD Drug ID
DMY13UR
VARIDT Drug ID
DR00954

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Sodium/glucose cotransporter 1 (SGLT1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sotagliflozin DMMLXA9 Heart failure BD10-BD13 Approved [2]
LIK-066 DM32NWD Heart failure BD10-BD13 Phase 2 [3]
YG1699 DM1NR1J Type-1 diabetes 5A10 Phase 2 [4]
1614235 + 2330672 DMD751X Type-2 diabetes 5A11 Phase 1 [3]
GSK1614235 DM7I1AQ Type-2 diabetes 5A11 Phase 1 [5]
LX2761 DM8ZS7T Type 2 diabetes 5A11 Phase 1 [6]
T-1095 DMGFS51 Diabetic complication 5A2Y Discontinued in Phase 2 [7]
KURAIDIN DMLDUJ1 Discovery agent N.A. Investigative [1]
KURARINONE DMH0G8W Discovery agent N.A. Investigative [1]
10-methoxy-N(1)-methylburnamine-17-O-veratrate DMJW25X Discovery agent N.A. Investigative [8]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting SLC5A2 messenger RNA (SLC5A2 mRNA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Bexagliflozin DMK56G0 Type 2 diabetes 5A11 Approved [9]
ISIS-SGLT2 DMDKAIC Type-2 diabetes 5A11 Phase 1 [10]
KURAIDIN DMLDUJ1 Discovery agent N.A. Investigative [1]
KURARINONE DMH0G8W Discovery agent N.A. Investigative [1]
10-methoxy-N(1)-methylburnamine-17-O-veratrate DMJW25X Discovery agent N.A. Investigative [8]
Alstiphyllanine F DMKRAEW Discovery agent N.A. Investigative [8]
Alstiphyllanine E DMTNQ5E Discovery agent N.A. Investigative [8]
Burnamine-17-O-3',4',5'-trimethoxybenzoate DMBO0WI Discovery agent N.A. Investigative [8]
Alstiphyllanine D DM2FLDJ Discovery agent N.A. Investigative [8]
O-spiroketal glucoside DM3FS62 Discovery agent N.A. Investigative [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
SLC5A2 messenger RNA (SLC5A2 mRNA) TTF8JAT SC5A2_HUMAN Inhibitor [1]
Sodium/glucose cotransporter 1 (SGLT1) TT2UE56 SC5A1_HUMAN Inhibitor [1]

References

1 Na+-glucose cotransporter (SGLT) inhibitory flavonoids from the roots of Sophora flavescens. Bioorg Med Chem. 2007 May 15;15(10):3445-9.
2 LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther. 2012 Aug;92(2):158-69.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 915).
4 ClinicalTrials.gov (NCT04956263) A Comparison of Postprandial Glucose After a Mixed Meal Tolerance Test, and the Metabolic Effects of Insulin Withdrawal in a Crossover Study of the Dual Systemic SGLT1 and SGLT2 Inhibitor YG1699, and the Selective SGLT2 Inhibitor Dapagliflozin in Subjects With Type 1 Diabetes. U.S.National Institutes of Health.
5 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
6 Clinical pipeline report, company report or official report of Lexicon Pharmaceuticals.
7 T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes. 1999 Sep;48(9):1794-800.
8 Alstiphyllanines E-H, picraline and ajmaline-type alkaloids from Alstonia macrophylla inhibiting sodium glucose cotransporter. Bioorg Med Chem. 2010 Mar 15;18(6):2152-2158.
9 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
10 Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
11 ortho-Substituted C-aryl glucosides as highly potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors. Bioorg Med Chem. 2010 Jun 15;18(12):4422-32.